Appointment of Prof. David Nutt as CSO

3 June 2025

Solvonis Therapeutics plc

("Solvonis" or the "Company")

Appointment of Professor David Nutt as Chief Scientific Officer

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, is pleased to announce that Professor David Nutt, who has served as Senior Scientific Advisor to the Company since July 2024, has been appointed to the Company's management team as Chief Scientific Officer ("CSO") with immediate effect.

Professor Nutt is one of the world's foremost authorities in brain science and psychiatric medicine, with a distinguished career spanning more than four decades. He holds the Edmond J. Safra Chair in Neuropsychopharmacology at Imperial College London, where he leads the Neuropsychopharmacology Unit within the Division of Brain Sciences. His research has significantly advanced the understanding and treatment of central nervous system ("CNS") disorders, particularly in addiction, depression, anxiety, and other high-burden mental health conditions.

Professor Nutt has authored over 600 peer-reviewed publications and several landmark texts on psychiatric illness, brain chemistry and CNS drug development. His work has played a pivotal role in translating neuroscience into effective clinical interventions. Professor Nutt is a Fellow of the Royal College of Physicians, the Royal College of Psychiatrists and the Academy of Medical Sciences and has held senior advisory roles with leading UK and European medical research institutions.

Professor David Nutt, CSO of Solvonis, commented: "It's a privilege to take on this expanded role at Solvonis at such a pivotal stage in the Company's growth. Solvonis is distinguished by its unwavering commitment to rigorous neuroscience, translational innovation, and clinically grounded development - all of which align closely with my own scientific philosophy. The pipeline reflects both ambition and focus, with the potential to deliver transformative treatments for brain disorders that continue to impose an immense personal and societal burden. I look forward to helping accelerate the development of therapies that are not only scientifically robust, but capable of making a real difference in patients' lives at scale.""

As CSO, Professor Nutt will lead the scientific strategy and clinical development of Solvonis' expanding pipeline, including:

· SVN-001 - a Phase 3-stage, proprietary combination of intravenous ketamine and relapse-prevention cognitive behavioural therapy ("CBT") for severe Alcohol Use Disorder ("AUD"), currently being evaluated across eight NHS Trusts in the UK. The trial is co-funded by the Medical Research Council ("MRC"), the National Institute for Health and Care Research ("NIHR") and Solvonis.

· SVN-002 - a patent-pending sublingual/buccal esketamine formulation, paired with therapy, targeting moderate to severe AUD for the US market. The programme is in Phase 2b planning under the FDA 505(b)(2) regulatory pathway.

· SVN-SDN-14 - a preclinical-stage programme focused on multi-receptor modulation (serotonin, dopamine, noradrenaline) to promote pro-social behaviour and improve safety relative to existing investigational therapies for trauma related mental health disorders, such as Post-Traumatic Stress Disorder ("PTSD").

· Solvonis' proprietary CNS compound library, comprising multiple patented chemical series that have completed hit-to-lead progression. Professor Nutt will oversee scientific direction, asset prioritisation, and translational development across the early-stage pipeline.

Professor Nutt's scientific leadership will be instrumental in shaping translational strategy, regulatory engagement, and clinical execution across the Company's portfolio.

This non-board appointment reinforces Solvonis' commitment to world-class neuroscience and to delivering innovation in areas of urgent, unmet clinical need.

Anthony Tennyson, CEO of Solvonis, commented: "David is one of the most accomplished neuroscientists of his generation. His contributions to our understanding of brain chemistry and psychiatric illness are unmatched, and his leadership will be central to advancing Solvonis' pipeline of novel therapeutics for addiction and mental health disorders. We are delighted that David has agreed to become Solvonis' CSO."

Enquiries:Solvonis Therapeutics plcAnthony Tennyson, CEO & Executive [email protected]Allenby Capital Limited (Financial Adviser and Joint Broker)Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)Guy McDougall (Sales & Corporate Broking)+44 (0) 20 3328 5656Singer Capital Markets (Joint Broker)Phil Davies+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds that target high-burden neuropsychiatric conditions with significant unmet need.

The company's lead programs address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 trials for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD program leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.

With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.